Market Place
Sourcing Support
Krystal Bio Updates On Gene Therapy For Rare Respiratory Diseases
12 Dec 2024 //
GLOBENEWSWIRE
Krystal Biotech to Present at Upcoming Investor Conferences
27 Nov 2024 //
GLOBENEWSWIRE
Krystal Biotech to Present at Stifel 2024 Healthcare Conference
12 Nov 2024 //
GLOBENEWSWIRE
Krystal Bio to Present at Guggenheim Securities Health Conference
06 Nov 2024 //
GLOBENEWSWIRE
Krystal Biotech Announces Q3 2024 Results and Business Updates
04 Nov 2024 //
GLOBENEWSWIRE
Krystal Biotech to Report Q3 2024 Results on November 4
28 Oct 2024 //
GLOBENEWSWIRE
Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
13 Sep 2024 //
GLOBENEWSWIRE
Krystal Biotech To Present At HC Wainwright Investment Conference
06 Sep 2024 //
GLOBENEWSWIRE
Krystal Biotech Reports Q2 2024 Results And Business Updates
05 Aug 2024 //
GLOBENEWSWIRE
Analysts Highlight Krystal`s Vyjuvek Launch Progress
05 Aug 2024 //
FIERCE PHARMA
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5
26 Jul 2024 //
GLOBENEWSWIRE
Krystal Biotech: Presenting At Goldman Sachs Healthcare Conference
05 Jun 2024 //
GLOBENEWSWIRE
Krystal Biotech To Present At American Thoracic Society 2024 Conference
15 May 2024 //
GLOBENEWSWIRE
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
08 May 2024 //
GLOBENEWSWIRE
Krystal touts topical gene therapy uptake, plots more launches
07 May 2024 //
FIERCE PHARMA
Krystal Biotech Announces Q1 2024 Results, Business Updates
06 May 2024 //
GLOBENEWSWIRE
Krystal Biotech At ARVO 2024 Ophthalmology Meeting
02 May 2024 //
GLOBENEWSWIRE
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
26 Apr 2024 //
GLOBENEWSWIRE
Krystal Doses First KB707 Lung Cancer Patient
22 Apr 2024 //
GLOBENEWSWIRE
Krystal Biotech to Present at the AACR 2024 Annual Meeting
04 Apr 2024 //
GLOBENEWSWIRE
Krystal Biotech Plans to Advance Eyedrop Gene Therapy That Cured Blindness
08 Mar 2024 //
PRESS RELEASE
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Krystal Biotech`s Vyjuvek launch sparks blockbuster hopes
26 Feb 2024 //
FIERCE PHARMA
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
GLOBENEWSWIRE
Krystal Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707
13 Feb 2024 //
GLOBENEWSWIRE
Krystal Announces Publication on the Application of B-VEC
08 Feb 2024 //
GLOBENEWSWIRE
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
04 Jan 2024 //
GLOBENEWSWIRE
Krystal Receives Orphan Drug Designation from the Japanese MHLW for B-VEC
19 Dec 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces EMA Validation of MAA for VYJUVEK
27 Nov 2023 //
GLOBENEWSWIRE
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
09 Nov 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Krystal`s topical gene therapy Vyjuvek gains steam: analyst
06 Nov 2023 //
FIERCE PHARMA
Krystal Biotech to Report Third Quarter 2023 Financial Results
30 Oct 2023 //
GLOBENEWSWIRE
Krystal Biotech to Present at Chardan 7th Annual Genetic Medicines Conference
28 Sep 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces FDA Clearance of Investigational NDA for KB408
21 Sep 2023 //
GLOBENEWSWIRE
Krystal Biotech to Present at Morgan Stanley 21st Annual Healthcare Conference
07 Sep 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces Orphan Drug Designation Granted to KB408
05 Sep 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
21 Aug 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces FDA Acceptance of IND Application for KB707
26 Jul 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407
03 Jul 2023 //
GLOBENEWSWIRE
Krystal Biotech to Present at Upcoming Investor Conferences
05 Jun 2023 //
GLOBENEWSWIRE
BSM supplies key component of Krystal Biotech’s DEB gene therapy
26 May 2023 //
PHARMACEUTICAL TECHNOLOGY
CSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy
22 May 2023 //
PR NEWSWIRE
Krystal Biotech Announces $160 Million Private Placement Equity Financing
22 May 2023 //
GLOBENEWSWIRE
FDA Approves First Topical Gene Therapy for Treatment of Wounds
20 May 2023 //
FDA
Krystal Biotech Announces 1Q 2023 FYR and Operational Highlights
08 May 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC
24 Apr 2023 //
GLOBENEWSWIRE
Krystal to Present at Association for Research in Vision & Ophthalmology Meeting
13 Apr 2023 //
GLOBENEWSWIRE
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
06 Mar 2023 //
GLOBENEWSWIRE
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
02 Mar 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Krystal gets EC’s orphan drug designation for KB407 to treat cystic fibrosis
21 Jan 2023 //
PHARMABIZ
Krystal Biotech Receives European Commission Orphan Designation for KB407
18 Jan 2023 //
GLOBENEWSWIRE
Krystal Biotech Announces FDA`s 3-Month Extension of BLA PDUFA Date for B-VEC
09 Jan 2023 //
GLOBENEWSWIRE
New England Journal of Medicine Publishes Phase 3 Data on B-VEC
14 Dec 2022 //
GLOBENEWSWIRE
Suma Krishnan co-founded a company to develop treatment for ‘the worst disease’
08 Dec 2022 //
ENDPTS
